Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

Medtronic PLC, FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Net income attributable to Medtronic
Net income attributable to noncontrolling interests
Net noncash charges
Change in operating assets and liabilities, net of acquisitions and divestitures
Net cash provided by operating activities
Cash paid for interest, net of tax1
Additions to property, plant, and equipment
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).


The financial data reveals notable fluctuations in the cash flow metrics of the company over the six-year period from 2020 to 2025.

Net cash provided by operating activities
The net cash generated from operating activities exhibited variability throughout the years. Initially, it decreased from 7,234 million USD in 2020 to 6,240 million USD in 2021. This was followed by a recovery to 7,346 million USD in 2022, marking the highest point in the observed period. Subsequently, it declined again to 6,039 million USD in 2023. The figures rose again to 6,787 million USD in 2024 and further increased to 7,044 million USD in 2025. Overall, while the cash flow from operations shows cyclical behavior, the terminal year value suggests a moderate improvement relative to the starting point.
Free cash flow to the firm (FCFF)
Free cash flow to the firm followed a somewhat similar pattern but with more pronounced declines and less consistent recovery. It started at 6,529 million USD in 2020 and fell to 5,427 million USD in 2021. A rebound occurred in 2022 to 6,473 million USD, though the magnitude was smaller compared to the operating cash flow rebound. In 2023, the FCFF sharply declined to 5,007 million USD, the lowest level recorded during the period. The next two years saw moderate increases to 5,833 million USD and 5,821 million USD in 2024 and 2025 respectively. Unlike the net operating cash flow, FCFF did not fully recover to the starting level by the end of the period.

In summary, the data indicates that while the company’s operational cash generation has experienced ups and downs, it tends to return to levels around its initial position by the end of the period. The free cash flow to the firm shows greater volatility and a less consistent recovery trajectory, suggesting that factors influencing capital expenditures or other investing cash flows may have affected the firm’s overall free cash generation capacity during these years.


Interest Paid, Net of Tax

Medtronic PLC, interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash paid for interest, before tax
Less: Cash paid for interest, tax2
Cash paid for interest, net of tax

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 See details »

2 2025 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =


Effective Income Tax Rate (EITR)
The effective income tax rate exhibited significant variability throughout the observed periods. It began at 21% in April 2020, decreased markedly to 6.8% in April 2021, and experienced a slight increase to 8.3% in April 2022. There was a pronounced rise to 29.5% in April 2023, followed by a moderate decline to 23.4% in April 2024. By April 2025, the rate further decreased to 16.6%. Overall, the trend indicates considerable fluctuations with peaks in 2023 and subsequent decreases, suggesting variability in taxable income or tax planning strategies.
Cash Paid for Interest, Net of Tax
The cash paid for interest showed some fluctuation over the six-year period. Starting at $508 million in April 2020, it increased slightly to $542 million in April 2021, then declined to $495 million by April 2022. A further decrease to $427 million occurred in April 2023. However, there was a notable increase in subsequent years to $633 million in April 2024 and $636 million in April 2025. This pattern suggests an initial reduction in interest expenses, potentially due to refinancing or reduction in debt levels, followed by a significant increase, possibly reflecting higher debt levels or rising interest rates in later years.

Enterprise Value to FCFF Ratio, Current

Medtronic PLC, current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.
EV/FCFF, Sector
Health Care Equipment & Services
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2025-04-25).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Medtronic PLC, historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.
EV/FCFF, Sector
Health Care Equipment & Services
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 See details »

2 See details »

3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.


Enterprise Value (EV)
The enterprise value exhibited significant fluctuation over the observed periods. Initially, it increased sharply from approximately 139,945 million USD in April 2020 to a peak of 183,640 million USD in April 2021. This was followed by a notable decline to 131,529 million USD in April 2022, with a relatively stable trend around 132,878 million USD in April 2023. Subsequent years saw a further decline to 120,025 million USD in April 2024, before experiencing a moderate rebound to 130,407 million USD in April 2025.
Free Cash Flow to the Firm (FCFF)
Free cash flow to the firm showed mixed performance across the periods. Starting at 6,529 million USD in April 2020, it decreased to 5,427 million USD in April 2021. It then improved to 6,473 million USD in April 2022, followed by a decline to 5,007 million USD in April 2023. The subsequent years displayed slight recovery and stabilization, with values close to 5,833 million USD in April 2024 and 5,821 million USD in April 2025.
EV to FCFF Ratio
This valuation metric demonstrated considerable volatility. The ratio increased sharply to 33.84 in April 2021 from 21.43 in April 2020, indicating significantly higher enterprise value relative to free cash flow. The ratio then decreased to 20.32 in April 2022, suggesting a more balanced valuation. However, it rose again to 26.54 in April 2023 before declining to 20.58 in April 2024 and slightly increasing to 22.4 in April 2025. These fluctuations imply varying market perceptions of the firm's cash flow generation relative to its valuation over time.
Overall Insights
The data reveal a cycle of valuation increases and decreases, with enterprise value peaking in 2021 before generally trending downward and then slightly recovering. Free cash flow to the firm showed somewhat less volatility but did not return to its initial high levels by the end of the period. The EV/FCFF ratio's fluctuations suggest changing investor sentiment or market conditions impacting the firm's assessed worth in relation to its cash flow generation capabilities. Such patterns may indicate external market influences or internal operational factors affecting both valuation and cash generation over the timeline.